Despite a good number available, cardiovascular diseases have become one of the diseases threatening human health with high morbidity and mortality, which warrants new drugs to be developed. Sacubitril-valsartan is a novel neuroendocrine inhibitor with a dual inhibition of angiotensin receptor and neprilysin, and is one of great breakthroughs in the management of cardiovascular diseases in the past decade. In this review, we summarize the role of sacubitril-valsartan in the treatment of cardiovascular diseases.